Safety Study of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma

Study Description

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Brief Summary:

Bortezomib will enhance the activity of dacarbazine against melanoma and soft tissue sarcoma. Weekly administration of the combination will prove to be feasible and tolerable at an appropriate dose.

Condition or disease	Intervention/treatment	Phase
Melanoma; Soft Tissue Sarcoma; Parathyroid Carcinoma; Small Cell Carcinoma of the Lung; Carcinoid Tumors	Drug: Dacarbazine and bortezomib	Phase 1

Detailed Description:

The primary objective is to determine recommended phase II doses for the combination dacarbazine and bortezomib administered weekly.

Secondary objectives are to determine the maximum tolerated dose combination and to observe anti-tumor activity in terms of response rate(s), duration of response, time to progression, and time on treatment (a measure of both antitumor activity and treatment tolerance).

Study Design

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Study Type :	Interventional (Clinical Trial)
Actual Enrollment :	17 participants
Intervention Model:	Single Group Assignment
Masking:	None (Open Label)
Primary Purpose:	Treatment
Official Title:	Phase I Trial of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma
Study Start Date :	September 2004
Actual Primary Completion Date :	October 2009
Actual Study Completion Date :	November 2013

Arms and Interventions

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm

Intervention/treatment

Experimental: A; dacarbazine + bortezomib

Drug: Dacarbazine and bortezomib; Level 0: Dacarbazine 190 mg/m2 + Bortezomib 1.0 mg/m2; Level 1: Dacarbazine 250 mg/m2 + Bortezomib 1.0 mg/m2; Level 2: Dacarbazine 250 mg/m2 + Bortezomib 1.3 mg/m2; Level 3: Dacarbazine 250 mg/m2 + Bortezomib 1.6 mg/m2; Level 4: Dacarbazine 330 mg/m2 + Bortezomib 1.6 mg/m2; Level 5: Dacarbazine 440 mg/m2 + Bortezomib 1.6 mg/m2; Level 6: Dacarbazine 580 mg/m2 + Bortezomib 1.6 mg/m2; Other Name: bortezomib (velcade)

Outcome Measures

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :

1. Safety as measured by serious adverse events [ Time Frame: 4 years ]

Eligibility Criteria

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Ages Eligible for Study:	18 Years and older (Adult, Senior)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

• Histologic diagnosis of cutaneous or mucosal melanoma, soft tissue sarcoma (STS), or an APUD (amine precursor uptake and decarboxylation) tumor. APUD tumors include parathyroid carcinoma, medullary carcinoma of the thyroid, small cell carcinoma of the lung, pheochromocytoma, islet cell tumors, carcinoid tumors, and malignant paraganglioma.
• Measurable or evaluable disease not appropriate for resection and/or radiation with curative intent. Patients with small cell carcinoma must have extended stage disease or, if limited stage disease, must have received at least one prior systemic therapy.
• Age 18 years or greater
• ECOG Performance Status 0 or 1
• Women must be post-menopausal, infertile as the result of a surgical procedure, or willing to use a medically accepted form of birth control (abstinence, hormonal contraceptive, intra-uterine device, diaphragm with spermicide, condon with spermicide) for the duration of study treatment. Men also must agree to use a medically accepted form of birth control for the duration of study treatment.

Exclusion Criteria:

• Uncontrolled brain metastatic disease
• Platelet count <100
• Absolute neutrophil count <1.5
• Blood transfusion or hematopoietic growth factors for cytopenia within one month of enrollment.
• Calculated or measured (Cockcroft and Gault formula) creatinine clearance <30 mL/minute
• AST > 3 times the upper limit of normal, unless elevation due to metastatic disease, in which case AST > 5 times the upper limit of normal
• Bilirubin > 2 mg/mL
• Grade 2 or greater peripheral neuropathy
• Hypersensitivity to bortezomib, boron, mannitol, or dacarbazine
• Pregnant or nursing
• Other investigational drugs within 14 days of enrollment
• Other medical or other condition(s) that in the opinion of the investigator/sub-investigator might compromise the objectives of the study

Contacts and Locations

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Locations

United States, New Hampshire
Dartmouth Hitchcock Medical Center
Lebanon, New Hampshire, United States, 03756
United States, Virginia
Massey Cancer Center/Virginia Commonwealth University
Richmond, Virginia, United States, 23298

Sponsors and Collaborators

Virginia Commonwealth University

Investigators

Principal Investigator:	Andrew Poklepovic, MD	Massey Cancer Center

More Information

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Additional Information:

Publication 

Responsible Party:	Virginia Commonwealth University
ClinicalTrials.gov Identifier:	NCT00580320 History of Changes
Other Study ID Numbers:	MCC-03740
First Posted:	December 24, 2007
Last Update Posted:	August 18, 2016
Last Verified:	August 2016

Keywords provided by Virginia Commonwealth University:

melanoma; soft tissue sarcoma; APUD tumor	dacarbazine; bortezomib; velcade

Additional relevant MeSH terms:

Carcinoma; Melanoma; Sarcoma; Carcinoid Tumor; Lung Neoplasms; Carcinoma, Small Cell; Small Cell Lung Carcinoma; Parathyroid Neoplasms; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms; Neuroendocrine Tumors; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms, Nerve Tissue	Nevi and Melanomas; Neoplasms, Connective and Soft Tissue; Adenocarcinoma; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Lung Diseases; Respiratory Tract Diseases; Carcinoma, Bronchogenic; Bronchial Neoplasms; Endocrine Gland Neoplasms; Head and Neck Neoplasms; Endocrine System Diseases; Parathyroid Diseases; Bortezomib